TABLE 3.

Pharmacokinetics of intramuscular obiltoxaximab^c

Study and dose (mg/kg)a	Postchallenge dosing schedule	Cmax (μg/ml)	Tmax (days)	AUC(0–∞) (μg/day/ml)	t1/2 (days)	CL/F (ml/day/kg)	Vz/F (ml/kg)
PEP 2
8	18 h	80.8	1.0	1,030	7.50	7.76	84.0
8	24 h	86.5	1.0	788	5.20	10.2	76.2
8b	36 h	60.8	1.0
16	18 h	165	1.0	2,120	8.44	7.54	91.9
16	24 h	119	1.0	1,990	9.85	8.03	114
16	36 h	140	0.50	1,600	8.23	10.0	119
PEP 3
16	24 h	142	1.0	2,190	10.4	7.00	110
16	36 h	132	0.50	1,540	7.09	10.0	106
16	48 h	104	3.0	2,040	12.6	8.00	143
Preexp
16	Day −3	152	1.6	1,940	9.95	8.55	117
16	Day −2	156	1.2	1,850	10.0	8.93	126
16	Day −1	149	1.8	1,990	9.23	8.26	108

^aAnimals were challenged with a target dose of 200 LD₅₀ equivalents of B. anthracis (Ames strain) spores. Due to mortality following challenge, PK parameters were based on composite mean concentrations from all animals per time point per dose group (male and female values combined), analyzed as one profile.

^bAll animals succumbed to anthrax and obiltoxaximab; therefore, concentration data were incomplete.

^cValues are combined-sex means.